Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2020 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CONFIDENTIAL | 24 | Q2 2023 | 0.0% |
Celldex Therapeutics, Inc. | 9 | Q4 2018 | 100.0% |
HYATT | 2 | Q4 2013 | 100.0% |
GELESIS HLDGS INC | 1 | Q1 2023 | 100.0% |
View KLP Enterprises, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Celldex Therapeutics, Inc. | December 09, 2016 | 6,865,006 | 5.7% |
View KLP Enterprises, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
13F-NT | 2024-08-12 |
13F-NT | 2024-05-13 |
13F-NT | 2024-02-14 |
13F-NT | 2023-11-15 |
13F-HR | 2023-08-15 |
13F-HR | 2023-05-15 |
13F-NT | 2023-02-14 |
13F-NT | 2022-11-14 |
13F-NT | 2022-08-01 |
View KLP Enterprises, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.